1 suspended, 1 unknown. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Suspended 1 |
Follow Nova Mentis Life Science Corp: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Investigation of Psilocybin on Behavioural and Cognitive Symptoms of Adults With Fragile X Syndrome Psilocybin, 1.5 mg - Fragile X Syndrome, Behavior | Phase 2 | Suspended | Nova Mentis Life Science Corp | 10 | 2023-03-28 | 2024-05-08 |
| Establishing a Diagnostic and Therapeutic Index in Autism Spectrum Disorder (ASD) and Fragile X Syndrome specimen collection - Autism Spectrum Disorder, Fra(X) Syndrome | Unknown | Nova Mentis Life Science Corp | 300 | 2021-11-01 | 2021-10-13 |
Fragile X Syndrome (2) · Autism Spectrum Disorder (1) · Behavior (1) · Cognitive Dysfunction (1) · Neurobehavioral Manifestations (1)
Psilocybin (1) · Specimen Handling (1)
Canada (1) · United States (1)
David Crowley, MD (1) · Julia V Perederiy, PhD (1) · Marvin Hausman, MD (1)